Bioorthogonal Chemistry: A Tool for Selective Labeling and Functionalization

Mohammad Heydari^*
*Correspondence: Mohammad Heydari, Department of Chemistry, Payame Noor University, Tehran, Iran, Email:

Keywords

Bioorthogonal chemistry • Chemical reactions • Biochemical processes

Introduction

Bioorthogonal chemistry refers to the use of chemical reactions that are orthogonal, or non-interfering, with the intricate web of biochemical processes that occur within living systems. Bioorthogonal reactions are designed to specifically target and modify a particular biomolecule of interest, minimizing collateral damage to other cellular components. The reactants and reagents used in bioorthogonal chemistry must be stable and readily available within biological environments, allowing for in vivo applications. Bioorthogonal reactions should occur quickly, enabling researchers to achieve their desired modifications within a reasonable timeframe [1]. The chosen bioorthogonal reactions should not interfere with native biological processes, ensuring minimal disruption to cellular functions.

Bioorthogonal chemistry allows for the selective labeling of proteins with various probes, including fluorescent dyes, biotin, or other small molecules. This labeling can be used for tracking protein localization, monitoring proteinprotein interactions and quantifying protein levels in cells and tissues. Modifying glycans (sugar molecules) on the surface of cells and proteins is crucial for understanding their roles in various biological processes [2]. Bioorthogonal chemistry enables the controlled manipulation of glycan structures, facilitating studies on cell adhesion, signaling and immune responses. Click chemistry reactions, such as the copper-free azide-alkyne cycloaddition, are widely used in bioorthogonal chemistry. They offer the ability to link biomolecules together with high efficiency and selectivity, making them valuable tools in the construction of bioconjugates for drug delivery and targeted therapy.

Description

Bioorthogonal chemistry plays a pivotal role in designing and engineering drug delivery systems. By attaching bioactive molecules to nanoparticles or other carriers using bioorthogonal reactions, researchers can improve drug targeting, bioavailability and controlled release. The incorporation of noncanonical amino acids with unique functional groups into proteins allows for the generation of modified proteins with enhanced or novel properties. This technique is employed for a range of applications, including enzyme engineering and the development of protein-based therapeutics. While bioorthogonal chemistry has proven invaluable in advancing our understanding of biological processes and developing innovative therapies, it is not without its challenges. One of the primary hurdles is the potential toxicity of the reagents used in these reactions. Researchers continually strive to develop more biocompatible and bioavailable bioorthogonal chemistries to minimize the impact on living systems [3-5].

Another challenge is the need for increased specificity and selectivity in bioorthogonal reactions. The desire to minimize off-target effects and enhance the precision of biomolecule modifications drives ongoing research into the development of improved reaction strategies. Looking to the future, bioorthogonal chemistry is expected to remain at the forefront of scientific innovation. Researchers are likely to refine existing techniques and discover novel bioorthogonal reactions, expanding the range of applications in fields such as cancer therapy, regenerative medicine and synthetic biology.

Conclusion

Bioorthogonal chemistry has emerged as a transformative tool for selectively labeling and functionalizing biomolecules in the complex milieu of living systems. Its applications are vast and continually expanding, offering researchers new ways to probe, manipulate and exploit the intricacies of biology. As bioorthogonal chemistry continues to evolve, we can expect a profound impact on our understanding of biology and the development of innovative treatments for a wide range of diseases.

References

1. Rozenbaum, Meir, Amilia Meir, Yarden Aharony and Orit Itzhaki, et al. "Gamma-delta CAR-T cells show CAR-directed and independent activity against leukemia."Front immunol 11 (2020): 1347.

   Google Scholar, Crossref, Indexed at

2. Xiao, Lin, Can Chen, Zhendong Li and Sumin Zhu, et al. "Large-scale expansion of Vγ9Vδ2 T cells with engineered K562 feeder cells in G-Rex vessels and their use as chimeric antigen receptor–modified effector cells."Cytotherapy20 (2018): 420-435.

   Google Scholar, Crossref, Indexed at

3. Bonneville, Marc, Rebecca L. O'brien and Willi K. Born. "γδ T cell effector functions: A blend of innate programming and acquired plasticity."Nat Rev Immunol10 (2010): 467-478.

   Google Scholar, Crossref, Indexed at

4. de Bruin, Renée CG, Sinéad M. Lougheed, Liza van der Kruk and Anita G. Stam, et al. "Highly specific and potently activating Vγ9Vδ2-T cell specific nanobodies for diagnostic and therapeutic applications."Clin Immunol169 (2016): 128-138.

   Google Scholar, Crossref, Indexed at

5. Hogan, Patrick G. "Calcium–NFAT transcriptional signalling in T cell activation and T cell exhaustion."Cell calcium63 (2017): 66-69.

   Google Scholar, Crossref, Indexed at